Skip to content

Medical emergency? What to do

Pfizer shares plunge after cholesterol drug fails

3-RXPublished December 6, 20064 min read

Key points

  • Shares in Pfizer Inc fell around 14 percent in European and pre-opening U.S. trade on Monday after the world's biggest drugmaker scrapped development of its most important experimental medicine.
  • Torcetrapib had been expected to fill a gap left when the patent on Lipitor, the world's biggest-selling drug with annual sales of $13 billion, expires in 2010 or 2011.
  • "These guys were already on the acquisition trail for new products and new technologies but the scale of what they would consider might now change," said Mike Ward, an analyst with Nomura Code Securities in London.
  • Ward said Pfizer might consider buying companies such as Wyeth or Amgen Inc, which offer assets in vaccines and antibodies, two important new areas for the group.

Shares in Pfizer Inc fell around 14 percent in European and pre-opening U.S. trade on Monday after the world's biggest drugmaker scrapped development of its most important experimental medicine.

Pfizer halted work on torcetrapib, which was designed to raise levels of "good" HDL cholesterol, because of increased deaths and heart problems among patients given the product in a late-stage trial.

Torcetrapib had been expected to fill a gap left when the patent on Lipitor, the world's biggest-selling drug with annual sales of $13 billion, expires in 2010 or 2011.

Its failure leaves Pfizer with a multibillion-dollar hole in its anticipated future revenue stream that the company will now have to try and fill by buying in other products.

"These guys were already on the acquisition trail for new products and new technologies but the scale of what they would consider might now change," said Mike Ward, an analyst with Nomura Code Securities in London.

"Rather than the $1 billion to $4 billion range of acquisitions. which has been fairly consistent Pfizer policy for a while, there will now be speculation that it could be almost anything."

Ward said Pfizer might consider buying companies such as Wyeth or Amgen Inc, which offer assets in vaccines and antibodies, two important new areas for the group.

Credit Suisse also said Pfizer should consider large acquisitions.

Pfizer shares fell more than 14 percent to $23.90 in electronic trading before the opening bell in New York, although the stock is still above its year low of $20.27.

The decision to scrap torcetrapib took investors by surprise, although there had been concerns that the drug caused elevations in blood pressure, itself a major risk of heart disease.

Just days ago, at a meeting with industry analysts and money managers, Pfizer executives pinned high hopes on torcetrapib and said they might seek U.S. approval for it next year.

"Short of Lipitor losing patent protection, the failure of torcetrapib is the biggest possible setback for Pfizer that could have happened," Heather Brilliant, an analyst for Morningstar Inc, said at the weekend.

Also last week, Pfizer ended a joint development program with Akzo Nobel for schizophrenia drug asenapine.

RIVALS GAIN

For some of Pfizer's rivals, however, the problems facing the New York-based giant are good news.

Industry analysts at Morgan Stanley said the failure of torcetrapib was an "important positive" for AstraZeneca Plc, since the product had been the biggest potential competitor to its fast-growing cholesterol drug Crestor.

After a shaky start, Crestor has established itself as an important driver of AstraZeneca sales and profits, thanks to clinical tests this year showing it can reverse the build-up of arterial plaque linked to heart attacks.

Worldwide sales of Crestor in the third quarter jumped 62 percent from a year earlier to $536 million.

AstraZeneca shares, which have been punished recently following setbacks for its own drugs in development, added around 1 percent in London.

Switzerland's Roche Holding might also benefit among European pharmaceutical companies, since it is developing a rival to torcetrapib licensed from Japan Tobacco Inc in October 2004, although some investors are wary the problems with torcetrapib could turn out to be a class effect.

Roche stock traded unchanged after an early advance.

UBS noted Roche had not seen any increases in blood pressure, the most likely reason for the deaths linked to torcetrapib, in a phase II study of its R1658 compound.

Another potential winner from Pfizer's woes is expected to be U.S. group Abbott Laboratories Inc, which is acquiring Kos Pharmaceuticals Inc Kos markets Niaspan, part of an older class of niacin medicines that also raise HDL.

Merck & Co Inc, meanwhile, is conducting trials of its own long-acting form of niacin, as well as of a separate drug that would be combined with it to prevent facial flushing -- a side effect of niacin.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underDrug News

Keep reading

Cancer

Experimental drug shrinks cancer tumors

An experimental cancer drug successfully shrank tumors in patients with different kinds of cancer, including typically hard-to-treat lung cancers, according to a new study. Oncologists said the research was…

4 min read

Cancer

Avastin Slows Resistant Ovarian Cancer

Progression of platinum-resistant ovarian cancer slowed by more than 50% in patients who received bevacizumab (Avastin) plus chemotherapy compared with nonplatinum chemotherapy alone, results of a randomized trial…

3 min read

Drug News

Prevnar trial results needed for CDC recommendation

Advisors to the U.S. Centers for Disease Control and Prevention on Wednesday will wait for results from a trial of Pfizer Inc's Prevnar 13 pneumonia vaccine before deciding whether to recommend its use in all adults…

1 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.